FDA Should Resolve Patent Dispute In AmCell Case, Delaware Court Rules
This article was originally published in The Gray Sheet
Executive Summary
FDA should clarify whether an exemption in U.S. patent law protects AmCell Corp. from a patent infringement suit by Nexell Therapeutics, according to a summary judgment by the federal district court in Wilmington, Delaware.
You may also be interested in...
Nexell Sues Sublicensee Miltenyi In Defense Of Stem Cell Purification Patents
Nexell Therapeutics' second move to defend patents covering the firm's proprietary stem cell purification technology kicked off with the recent filing of a patent suit in Delaware federal court.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.